In Vitro and Ex Vivo Inhibition of Human Telomerase by Anti-HIV Nucleoside Reverse Transcriptase Inhibitors (NRTIs) but Not by Non-NRTIs
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Telomerase is a specialized reverse transcriptase responsible for the de novo synthesis of telomeric DNA repeats. In addition to its established reverse transcriptase and terminal transferase activities, recent reports have revealed unexpected cellular activities of telomerase, including RNA-dependent RNA polymerization. This telomerase characteristic, distinct from other reverse transcriptases, indicates that clinically relevant reverse transcriptase inhibitors might have unexpected telomerase inhibition profiles. This is particularly important for the newer generation of RT inhibitors designed for anti-HIV therapy, which have reported higher safety margins than older agents. Using an in vitro primer extension assay, we tested the effects of clinically relevant HIV reverse transcriptase inhibitors on cellular telomerase activity. We observed that all commonly used nucleoside reverse transcriptase inhibitors (NRTIs), including zidovudine, stavudine, tenofovir, didanosine and abacavir, inhibit telomerase effectively in vitro. Truncated telomere synthesis was consistent with the expected mode of inhibition by all tested NRTIs. Through dose-response experiments, we established relative inhibitory potencies of NRTIs on in vitro telomerase activity as compared to the inhibitory potencies of the corresponding dideoxynucleotide triphosphates. In contrast to NRTIs, the non-nucleoside reverse transcriptase inhibitors (NNRTIs) nevirapine and efavirenz did not inhibit the primer extension activity of telomerase, even at millimolar concentrations. Long-term, continuous treatment of human HT29 cells with select NRTIs resulted in an accelerated loss of telomere repeats. All tested NRTIs exhibited the same rank order of inhibitory potencies on telomerase and HIV RT, which, according to published data, were orders-of-magnitude more sensitive than other DNA polymerases, including the susceptible mitochondria-specific DNA polymerase gamma. We concluded that telomerase activity could be inhibited by common NRTIs, including currently recommended RTI agents tenofovir and abacavir, which warrants large-scale clinical and epidemiological investigation of the off-target effects of long-term highly active antiretroviral therapy (HAART) with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Contrastingly, other studies have suggested that the use of NRTIs may potentially activate the tumour suppressor gene p53 in healthy cells, inhibiting telomerase to cause cell death [183,184,185].”
From Current State of Therapeutics for HTLV-1 (2024) · cites this paper as [184]
Experimental — accuracy not yet measuredIn the citing paper
“Moreover, NRTIs can also inhibit telomerase and are thought to contribute to accelerated aging phenotypes associated with HIV patients (Hukezalie et al., 2012; Leeansyah et al., 2013).”
From Cytoplasmic DNA: sources, sensing, and role in aging and disease (2021) · cites this paper as Hukezalie et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Telomerase Catalytic Subunit Homologs from Fission Yeast and Human
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., Harley, C. B., & Cech, T. R. (1997) · Science · doi:10.1126/science.277.5328.955 · Cited by 2,256
The RNA Component of Human Telomerase
Feng, J., Funk, W. D., Wang, S.-S., Weinrich, S. L., Avilion, A. A., Chiu, C.-P., Adams, R. R., Chang, E., Allsopp, R. C., Yu, J., et al. (1995) · Science · doi:10.1126/science.7544491 · Cited by 2,227 · cited 1×
“The catalytic core of the telomerase enzyme is a ribonucleoprotein composed of telomerase reverse transcriptase (TERT), the catalytic subunit [5], and telomerase RNA (TER) [6].”
BackgroundCounter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096 · cited 1×
“When telomeres reach a critical length, cellular surveillance mechanisms are activated and cellular proliferation ceases, either by permanent cell-cycle arrest, known as senescence, or by apoptosis [2,3].”
BackgroundHow Shelterin Protects Mammalian Telomeres
Palm, W., & de Lange, T. (2008) · Annual Review of Genetics · doi:10.1146/annurev.genet.41.110306.130350 · Cited by 1,802 · cited 1×
“Telomeres are comprised of simple DNA repeats and are packaged in a sequence-specific manner with the six-member protein complex known as shelterin [1].”
BackgroundThompson, M. A., Aberg, J. A., Cahn, P., Montaner, J. S. G., Rizzardini, G., Telenti, A., Gatell, J. M., Günthard, H. F., Hammer, S. M., Hirsch, M. S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1004 · Cited by 722
Effros, R. B., Fletcher, C. V., Gebo, K., Halter, J. B., Hazzard, W. R., Horne, F. M., Huebner, R. E., Janoff, E. N., Justice, A. C., Kuritzkes, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590150 · Cited by 539
Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins
Martínez, P., & Blasco, M. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3025 · Cited by 468 · cited 1×
“changes in telomeric repeat sequences–are recognized as signals of DNA damage, leading to the temporary halt of cell proliferation, or cell death [38,39].”
BackgroundAn RNA-dependent RNA polymerase formed by TERT and the RMRP RNA
Maida, Y., Yasukawa, M., Furuuchi, M., Lassmann, T., Possemato, R., Okamoto, N., Kasim, V., Hayashizaki, Y., Hahn, W. C., & Masutomi, K. (2009) · Nature · doi:10.1038/nature08283 · Cited by 384
Haendeler, J., Dröse, S., Büchner, N., Jakob, S., Altschmied, J., Goy, C., Spyridopoulos, I., Zeiher, A. M., Brandt, U., & Dimmeler, S. (2009) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.109.185546 · Cited by 375 · cited 2×
“The RdRP activity of TERT is associated with the enzyme’s intracellular trafficking to the mitochondria, perhaps as a response to oxidative stress [21,22,23].”
Background
Cited by
LINE1 Derepression in aged wild-type and SIRT6-deficient mice drives inflammation
Simon, M., Van Meter, M., Ablaeva, J., Ke, Z., Gonzalez, R. S., Taguchi, T., De Cecco, M., Leonova, K. I., Kogan, V., Helfand, S. L., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.014 · Cited by 498
Cytoplasmic DNA: sources, sensing, and role in aging and disease
Miller, K. N., Victorelli, S. G., Salmonowicz, H., Dasgupta, N., Liu, T., Passos, J. F., & Adams, P. D. (2021) · Cell · doi:10.1016/j.cell.2021.09.034 · Cited by 288
Oxidative guanine base damage regulates human telomerase activity
Fouquerel, E., Lormand, J., Bose, A., Lee, H.-T., Kim, G. S., Li, J., Sobol, R. W., Freudenthal, B. D., Myong, S., & Opresko, P. L. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3319 · Cited by 182
The Impact of HIV- and ART-Induced Mitochondrial Dysfunction in Cellular Senescence and Aging
Schank, M., Zhao, J., Moorman, J. P., & Yao, Z. Q. (2021) · Cells · doi:10.3390/cells10010174 · Cited by 171
“NRTIs, but NNRTIs, have also been shown to inhibit telomerase function both in vitro and in vivo, while also being incorporated into telomeric DNA, leading to chain termination and often cell death [131].”
BackgroundNew prospects for targeting telomerase beyond the telomere
Arndt, G. M., & MacKenzie, K. L. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.55 · Cited by 132
Basic science and pathogenesis of ageing with HIV: potential mechanisms and biomarkers
Lagathu, C., Cossarizza, A., Béréziat, V., Nasi, M., Capeau, J., & Pinti, M. (2017) · AIDS · doi:10.1097/qad.0000000000001441 · Cited by 110
Zanet, D. L., Thorne, A., Singer, J., Maan, E. J., Sattha, B., Campion, A. L., Soudeyns, H., Pick, N., Murray, M. C. M., Money, D., et al. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu051 · Cited by 117
“The fact that few study participants (22/163) were currently treated with the NRTIs showing highest telomerase inhibition in vitro (ie, stavudine, zidovudine, or didanosine [12]) may explain the lack of association between cART and LTL.”
BackgroundSelf-citationPremature aging and immune senescence in HIV-infected children
Gianesin, K., Noguera-Julian, A., Zanchetta, M., Del Bianco, P., Petrara, M. R., Freguja, R., Rampon, O., Fortuny, C., Camós, M., Mozzo, E., et al. (2016) · AIDS · doi:10.1097/qad.0000000000001093 · Cited by 96
“Nucleoside reverse transcriptase inhibitors have been shown to inhibit telomerase activity in replicating cell lines in vitro, leading to accelerated shortening of telomere length [11,12].”
Aging and HIV/AIDS: pathogenetic role of therapeutic side effects
Torres, R. A., & Lewis, W. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.142 · Cited by 118
Telomere Maintenance as a Target for Drug Discovery
Sekaran, V. G., Soares, J., & Jarstfer, M. B. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400528t · Cited by 100
Telomerase as a Cancer Target. Development of New Molecules
Mengual Gomez, D. L., Armando, R. G., Cerrudo, C. S., Ghiringhelli, P. D., & Gomez, D. E. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160212122425 · Cited by 73
Mechanisms of telomerase inhibition by oxidized and therapeutic dNTPs
Sanford, S. L., Welfer, G. A., Freudenthal, B., & Opresko, P. L. (2020) · Nature Communications · doi:10.1038/s41467-020-19115-y · Cited by 67
Berrino, E., Angeli, A., Zhdanov, D. D., Kiryukhina, A. P., Milaneschi, A., Luca, A. D., Bozdağ, M., Carradori, S., Selleri, S., Bartolucci, G., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00636 · Cited by 61
Hsieh, A. Y. Y., Saberi, S., Ajaykumar, A., Hukezalie, K. R., Gadawski, I., Sattha, B., & Côté, H. C. F. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.01.004 · Cited by 52
Self-citationDeficiency in DNA damage response, a new characteristic of cells infected with latent HIV-1
Piekna‐Przybylska, D., Sharma, G., Maggirwar, S. B., & Bambara, R. A. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1312225 · Cited by 52
“We analyzed DDR by exposing cells to high doses of the anti-HIV class of NAs called nucleoside reverse transcriptase inhibitors (NRTIs), choosing AZT (azidothymidine, zivudine) and d4T (stavudine), which are known to incorporate into genomic DNA, affect telomerase and to induce oxidative stress.(36,38-46)”
BackgroundMethodChiappini, E., Bianconi, M., Dalzini, A., Petrara, M. R., Galli, L., Giaquinto, C., & De Rossi, A. (2018) · Aging · doi:10.18632/aging.101622 · Cited by 46
“NRTIs inhibition of TERT, leading to premature telomeres shortening Liu X et al, 2007 Tressler R et al, 2012 Hukezalie KR et al, 2012 [83] [82] [84]”
BackgroundTelomerase: A prominent oncological target for development of chemotherapeutic agents
Vishwakarma, K., Dey, R., & Bhatt, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115121 · Cited by 46
Chiappini, E., Berti, E., Gianesin, K., Petrara, M. R., Galli, L., Giaquinto, C., de Martino, M., & Rossi, A. D. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.02.002 · Cited by 45
“telomerase activity in replicating cell lines in vitro leading to accelerated shortening of telomere length [78–80].”
BackgroundBeyond the polymerase-γ theory: Production of ROS as a mode of NRTI-induced mitochondrial toxicity
Smith, R. L., Tan, J. M. E., Jonker, M. J., Jongejan, A., Buissink, T., Veldhuijzen, S., van Kampen, A. H. C., Brul, S., & van der Spek, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187424 · Cited by 45
“In vitro experiments commonly use concentrations between 10–200μM [11,74,75].”
BackgroundOvercoming Therapy Resistance in Colon Cancer by Drug Repurposing
Zarif, T. E., Yibirin, M., Oliveira-Gomes, D. D., Machaalani, M., Nawfal, R., Carlini, G. B., Bahmad, H. F., & Bitar, N. (2022) · Cancers · doi:10.3390/cancers14092105 · Cited by 39
“Tenofovir also inhibits the activity of human telomerase [119], a crucial enzyme for tumorigenesis and cancer proliferation, whose inhibition represents a promising therapeutic strategy in cancer treatment [120,121].”
BackgroundGonzález‐Serna, A., Ajaykumar, A., Gadawski, I., Muñoz‐Fernández, M. Á., Hayashi, K., Harrigan, P. R., & Côté, H. C. F. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001446 · Cited by 36
Self-citationAging of the human innate immune system in HIV infection
Zapata, H. J., & Shaw, A. C. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.06.007 · Cited by 35
The far-reaching HAND of cART: cART effects on astrocytes
Gonzalez, H., Podany, A. T., Al‐Harthi, L., & Wallace, J. (2020) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-020-09907-w · Cited by 36
Biological Aging and Immune Senescence in Children with Perinatally Acquired HIV
Dalzini, A., Petrara, M. R., Ballin, G., Zanchetta, M., Giaquinto, C., & Rossi, A. D. (2020) · Journal of Immunology Research · doi:10.1155/2020/8041616 · Cited by 38
“In vitro studies showed that NRTIs inhibit telomerase causing an accelerated erosion of telomeres [53, 54, 187, 188]; recent studies argued that the e ff ect of prophylaxis and therapy is negligible compared to that of the infection itself [56].”
Montejano, R., Stella-Ascariz, N., Monge, S., Bernardino, J. I., Valero, I., Montes, M., Valencia, E., Martín‐Carbonero, L., Moreno, V., González‐García, J., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy364 · Cited by 35
Stella-Ascariz, N., Montejano, R., Rodríguez-Centeno, J., Alejos, B., Schwimmer, C., Bernardino, J. I., Rodés, B., Allavena, C., Hoffmann, C., Gisslén, M., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy399 · Cited by 36
Molecular targeting for treatment of human T-lymphotropic virus type 1 infection
Soltani, A., Hashemy, S. I., Zahedi Avval, F., Soleimani, A., Rafatpanah, H., Rezaee, S. A., Griffith, R., & Mashkani, B. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.139 · Cited by 31
Dalzini, A., Ballin, G., Domínguez‐Rodríguez, S., Rojo, P., Petrara, M. R., Foster, C., Cotugno, N., Ruggiero, A., Nastouli, E., Klein, N. J., et al. (2021) · Journal of the International AIDS Society · doi:10.1002/jia2.25847 · Cited by 30
“Accelerated shortening of telomeres may also be an adverse effect of nucleoside reverse transcriptase inhibitors in ART [12,13].”
BackgroundBlanco, J. R., Jarrín, I., Martínez, A., Siles, E., Larráyoz, I. M., Cañuelo, A., Gutiérrez, F., González‐García, J., Vidal, F., & Moreno, S. (2014) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000398 · Cited by 28
Bollmann, F. M. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.04.028 · Cited by 27
“This is in line with the finding that non-nucleoside reverse transcriptase inhibitors, which do not show pronouncedmitochondrial toxicity, do not inhibit telomerase [37].”
BackgroundResultChoice of antiretroviral therapy differentially impacts survival of HIV-infected CD4 T cells
Cummins, N. W., Sainski, A. M., Natesampillai, S., Bren, G. D., & Badley, A. D. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-1 · Cited by 24
“A variety of reports suggest that different classes of antiretroviral agents have off target effects [9,10] and differ in their ability to impact apoptosis – for example efavirenz has been suggested to be pro-apoptotic [11], whereas peptidomimetic protease inhibitors (eg.”
BackgroundCurrent State of Therapeutics for HTLV-1
Wang, T. T., Hirons, A., Doerflinger, M., Morris, K. V., Ledger, S., Purcell, D. F. J., Kelleher, A. D., & Ahlenstiel, C. L. (2024) · Viruses · doi:10.3390/v16101616 · Cited by 22
The transcription factor PAX5 activates human LINE1 retrotransposons to induce cellular senescence
Tang, H., Yang, J., Xu, J., Zhang, W., Geng, A., Jiang, Y., & Mao, Z. (2024) · EMBO Reports · doi:10.1038/s44319-024-00176-9 · Cited by 22
“Some research has reported that NRTIs could affect telomerase activity, and their off-target effects increase the risk of normal cells undergoing cellular senescence (Leeansyah et al, 2013; Hukezalie et al, 2012).”
Retrotransposons and piRNA: The missing link in central nervous system
Rajan, K. S., & Ramasamy, S. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.05.017 · Cited by 23
“Nucleoside reverse transcriptase inhibitors (NRTIs) such as zidovudine can silence, both telomerase reverse transcriptase and retrotransposon reverse transcriptase (Hukezalie et al., 2012).”
BackgroundQuirós-Roldán, E., Properzi, M., Paghera, S., Raffetti, E., Castelli, F., & Imberti, L. (2020) · Scientific Reports · doi:10.1038/s41598-020-67100-8 · Cited by 18
Rodríguez-Centeno, J., Esteban-Cantos, A., Montejano, R., Stella-Ascariz, N., Buckley, R. D. M., Mena-Garay, B., Saiz-Medrano, G., Alejos, B., Jiménez-González, M., Bernardino, J. I., et al. (2022) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab492 · Cited by 18
Pitfalls of Antiretroviral Therapy: Current Status and Long-Term CNS Toxicity
Rudd, H., & Toborek, M. J. (2022) · Biomolecules · doi:10.3390/biom12070894 · Cited by 19
Solomon, A. E., Tennakoon, S., Leeansyah, E., Arribas, J. R., Hill, A. M., van Delft, Y., Moecklinghoff, C., & Lewin, S. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109718 · Cited by 20
“Nucleos(t)ide reverse transcriptase inhibitors (NRTI) that inhibit HIV RT also inhibit telomerase activity in vitro [11,12] via inhibition of telomerase RT [13] and may potentially contribute to”
BackgroundHsiao, C.-B., Bedi, H., Gomez, R., Khan, A., Meciszewski, T., Aalinkeel, R., Khoo, T. C., Sharikova, A. V., Khmaladze, A. T., & Mahajan, S. D. (2021) · Vaccines · doi:10.3390/vaccines9070721 · Cited by 17
“Telomerase activity is also inhibited by currently recommended RTI agents, such as tenofovir and abacavir [12,13].”
BackgroundWard, J. R., Khan, A., Torres, S., Crawford, B., Nock, S. L., Frisbie, T. J., Moran, J. V., & Longworth, M. S. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac802 · Cited by 23
“Didanosine and Zidovudine have been shown to inhibit retrotransposition in different organisms and different cell types (73,74); it also should be noted that these NRTIs also inhibit telomerase (75,76).”
BackgroundSchoepf, I. C., Thorball, C. W., Ledergerber, B., Kootstra, N. A., Reiss, P., Raffenberg, M., Engel, T., Braun, D. L., Hasse, B. K., Thurnheer, C., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab603 · Cited by 15
Molina-Carrión, S., Brochado‐Kith, O., González‐García, J., Berenguer, J., Díez, C., Llop, E., Hontañón, V., Ibáñez, L., Montes, M., Resino, S., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9082407 · Cited by 14
“However, most ART regimens contain nucleoside reverse transcriptase inhibitors (NRTIs), which could inhibit telomerase activity [5].”
BackgroundSaberi, S., Kalloger, S. E., Zhu, M. M. T., Sattha, B., Maan, E. J., van Schalkwyk, J., Money, D., Côté, H. C. F., & the CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children (CARMA) (2019) · PLoS ONE · doi:10.1371/journal.pone.0212273 · Cited by 15
Self-citationThe Impact of HIV on Early Brain Aging—A Pathophysiological (Re)View
Lazăr, M., Moroti, R., Barbu, E. C., Chițu, C. E., Tilişcan, C., Erculescu, T. M., Rosca, R. R., Frasila, S., Schmilevschi, E. T., Simion, V., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13237031 · Cited by 13
Tolomeo, M., Tolomeo, F., & Cascio, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073184 · Cited by 14
Kalyan, S., Pick, N., Mai, A., Murray, M. C. M., Kidson, K. M., Chu, J., Albert, A., Côté, H. C. F., Maan, E. J., Goshtasebi, A., et al. (2018) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph15051018 · Cited by 14
“Treatments, including nucleoside reverse transcriptase inhibitors (NRTI), can induce mtDNA alterations [22] and may accelerate telomere loss [23], a phenomenon that has been linked with age-associated diseases, such as osteoporosis, in some [24], but not all, studies [25].”
BackgroundSelf-citationWang, J., Liu, L., & Ma, H. (2016) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2016.08.021 · Cited by 11
Paghera, S., Quirós-Roldán, E., Sottini, A., Properzi, M., Castelli, F., & Imberti, L. (2019) · Immunity & Ageing · doi:10.1186/s12979-019-0166-7 · Cited by 11
Li, G., Lewis, R. D., Mishra, N., & Axiotis, C. A. (2014) · Leukemia Research · doi:10.1016/j.leukres.2014.07.001 · Cited by 11
Fattore, L., Malpicci, D., Milite, C., Castellano, S., Sbardella, G., Botti, G., Ascierto, P. A., Mancini, R., & Ciliberto, G. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00633-7 · Cited by 10
The Regulation and Immune Signature of Retrotransposons in Cancer
Alkailani, M. I., & Gibbings, D. (2023) · Cancers · doi:10.3390/cancers15174340 · Cited by 10
Stella-Ascariz, N., Montejano, R., Pintado‐Berninches, L., Monge, S., Bernardino, J. I., Valero, I., Montes, M., Mingorance, J., Perona, R., & Arribas, J. R. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001154 · Cited by 12
“This inhibition is not observed with nonnucleoside reverse transcriptase inhibitors.(12) Recently, Leeansyah and collaborators reported that tenofovir (TFV)(13) at therapeutic concentrations is a potent inhibitor of telomerase Received for publication May 24, 2016; accepted July 29, 2016.”
BackgroundMacamo, E. D., Mkhize‐Kwitshana, Z. L., Mthombeni, J. Q., & Naidoo, P. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46070431 · Cited by 9
González‐Serna, A., Ferrando‐Martínez, S., Tarancón‐Díez, L., Pablo-Bernal, R. S. D., Domínguez-Molina, B., Jiménez, J. L., Muñoz‐Fernández, M. Á., Leal, M., & Ruíz-Mateos, E. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1367-5 · Cited by 11
“Moreover, NRTIs regimens have been associated with shortening of telomeres [8, 29].”
BackgroundHow DNA damage and non-canonical nucleotides alter the telomerase catalytic cycle
Sanford, S. L., Welfer, G. A., Freudenthal, B., & Opresko, P. L. (2021) · DNA repair · doi:10.1016/j.dnarep.2021.103198 · Cited by 10
Lombardi, F., Sanfilippo, A., Fabbiani, M., Borghetti, A., Ciccullo, A., Tamburrini, E., & Giambenedetto, S. D. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad237 · Cited by 9
Per2 Upregulation in Circulating Hematopoietic Progenitor Cells During Chronic HIV Infection
Bordoni, V., Tartaglia, E., Refolo, G., Sacchi, A., Grassi, G., Antinori, A., Fimia, G. M., & Agrati, C. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00362 · Cited by 8
“In fact, it was reported that the ART regimens containing the nucleoside analog reverse transcriptase inhibitors can alter telomerase reverse transcriptase activity, resulting in telomere length shortening in leukocytes (Hukezalie et al., 2012; Leeansyah et al., 2013; Lagathu et al., 2017).”
BackgroundBukic, E., Milašin, J., Toljić, B., Jadzic, J. S., Jevtović, D., Obradović, B., & Dragović, G. (2023) · Biology · doi:10.3390/biology12091210 · Cited by 7
“Although older studies indicated a negative effect of cART on telomere length [24,51,54], several recent studies presented different results.”
Ajaykumar, A., Soudeyns, H., Kakkar, F., Brophy, J. C., Bitnun, A., Alimenti, A., Albert, A., Money, D., Côté, H. C. F., CIHR Team in Cellular Aging and HIV Comorbidities in Women and Children, et al. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix618 · Cited by 8
Self-citationSubashini, D., Dinesha, T. R., Srirama, R. B., Boobalan, J., Poongulali, S., Chitra, D. A., Mothi, S. N., Solomon, S. S., Saravanan, S., Solomon, S., et al. (2018) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_1144_16 · Cited by 7
“Duration of infection in months, median (IQR) NA 36 (12-61) 83 (32-123)”
BackgroundCôté, H. C. F., & Hsieh, A. Y. Y. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy365 · Cited by 7
Self-citationApetroaei, M.-M., Baliou, S., Ιωάννου, Π., Fragkiadaki, P., Ștefan, G., Nedea, M. I., Burcea-Dragomiroiu, G.-T.-A., Velescu, B. Ș., Docea, A. O., Udeanu, D. I., et al. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040273 · Cited by 6
“Additionally, NRTIs are integrated into telomeric DNA, which can cause chain termination and cell death [188].”
Hearps, A. C., Schafer, K. R., High, K. P., & LANDAY, A. L. (2015) · Springer eBooks · doi:10.1007/978-3-319-23246-1_17 · Cited by 6
Gomes-da-Silva, N. C., Almeida, A. D. F., Severino, P., Al-Qahtani, M. H., Alencar, L. M. R., Fechine, P. B. A., Ricci‐Júnior, E., Vendrame, L. F. O., da Rocha, J. A. P., Fagan, S. B., et al. (2025) · ACS Applied Bio Materials · doi:10.1021/acsabm.5c00182 · Cited by 5
Tempest, N., Edirisinghe, D. N., Lane, S., & Hapangama, D. K. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.08.027 · Cited by 6
Wang, Y., Brummel, S. S., Beilstein-Wedel, E. E., Dagnall, C. L., Hazra, R., Kacanek, D., CHADWICK, E. G., Marsit, C. J., Chanock, S. J., Savage, S. A., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002317 · Cited by 5
“including ZDVare known to inhibit telomerase activity in vitro [4,5], it has been postulated that telomere length in individuals taking ZDV could be shorter than normal.”
BackgroundRelationship of Telomere Length to Fat Redistribution in HIV
Iyengar, S., Côté, H. C. F., Fitch, K. V., Torriani, M., Feldpausch, M. N., & Srinivasa, S. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa523 · Cited by 4
“Antiretroviral therapy (ART) is also associated with TL shortening in vitro, but human studies suggest that ART may be protective for leukocyte TL [7, 8].”
BackgroundSelf-citationAntiretroviral therapy–induced toxicity is associated with increased mRNA expression of telomerase
Li, M., Foli, Y., Amakye, N. Y., Klein, T. M., Selvaraj, S., Lu, L., & Paintsil, E. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.520 · Cited by 5
“In vitro studies have shown that NRTIs can also inhibit hTERT activity, leading to progressive shortening of telomere length, although in vivo studies have not corroborated this finding.(9,10) It has been hypothesized that inhibition of hTERT by ART could contribute to the premature aging in HIV-infected individuals.”
BackgroundHu, J., Mao, T., Huang, K., Yang, S., Yu, W., Huang, J., Jin, S., Sun, C., Jiapaer, Z., & Wang, X. (2026) · Cell Cycle · doi:10.1080/15384101.2025.2611968 · Cited by 3
Xu, J., de Oliveira, D. M., Trudeau, M. A., Yang, Y., Chin, J. J. Y., Sin, D. D., Sandford, A. J., & Wong, J. M. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-83686-z · Cited by 3
Self-citationInhibition of retrotransposition improves health and extends lifespan of SIRT6 knockout micePreprint
Simon, M., Meter, M. V., Ablaeva, J., Ke, Z., González, R. S., Taguchi, T., Cecco, M. D., Leonova, K. I., Kogan, V., Helfand, S. L., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/460808 · Cited by 3
“Additionally, NRTIs are known to inhibit telomerase and are believed to contribute to observations of accelerated aging in HIV patients (Hukezalie et al., 2012; Leeansyah et al., 2013).”
BackgroundRepurposing Drugs for Overcoming Therapy Resistance in Colon Cancer – A Review
Darvishi, M., Chekeni, A. M., Fazelhosseini, M., Iqbal, Z., Mirza, M. A., Aslam, M., & Bayrakdar, E. T. A. (2024) · Journal of Angiotherapy · doi:10.25163/angiotherapy.829423 · Cited by 3
Zachry, W., Griffith, J. M., Wegzyn, C. M., D'Amico, R. D., Woodward, W. C., & Qian, Q. X. (2013) · Future Virology · doi:10.2217/fvl.13.68 · Cited by 2
“Evidence suggests that NRTIs act as inhibitors of HIV reverse transcriptase and also inhibit other reverse transcriptases, including telomerase, which maintain telomeres, the nucleoprotein structures found at the end of chromosomes [28].”
BackgroundChen, Y. (2019) · Louisiana State University · doi:10.31390/gradschool_dissertations.4974 · Cited by 1
Zanet, D. L. (2013) · cIRcle (University of British Columbia) · doi:10.14288/1.0165594
“Telomerase inhibition and subsequent telomere shortening has been shown with a number of currently recommended NRTIs [7-9,132].”
BackgroundInfluentialSingh, S., Sharma, B., & Siddiqi, N. J. (2019) · Journal of Clinical Research in HIV AIDS and Prevention · doi:10.14302/issn.2324-7339.jcrhap-19-3070
Antiretroviral therapy and its cerebral vascular toxicity
Rudd, H., & Toborek, M. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-99744-7.00030-4
Novel effects of reverse transcriptase inhibitor supplementation in skeletal muscle of old mice
Osburn, S. C., Smith, M., Wahl, D., & LaRocca, T. J. (2025) · Physiological Genomics · doi:10.1152/physiolgenomics.00115.2024
Ye, J., Fan, L., Bär, C., Thum, T., Plettenburg, O., Cox, R. J., & Zeilinger, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-00230-z
“The ATP-binding site shares structural homology with the ATP-binding site of HIV reverse transcriptase, which has enabled the repurposing of several antiviral reverse transcriptase inhibitors for cancer treatment 13,14 .”
Sara, S. (2018) · cIRcle (University of British Columbia)
Analysis of Leukocyte Telomere Length in Brazilian People Living with HIV with and Without Cancer
Silvestre, R. T., Chantre-Justino, M., Bragante, M. A., Carvalho, P. L., Delmonico, L., Alves, G., Ornellas, M. H., & de Lima, D. B. (2026) · OBM Genetics · doi:10.21926/obm.genet.2601326
Beaupère, C. (2014) · theses.fr (ABES) · doi:10.70675/a75378b0z2c4fz47f6z99edz3a60a03b7ee3 · Cited by 1
Bukic, E., Dragović, G., & Milašin, J. (2025) · Medicinski podmladak · doi:10.5937/mp76-46748
“Efavirenz pripada antiretrovirusnim lekovima iz klase nenukleozidnih inhibitora reverzne transkriptaze (NNIRT), enzima neophodnog za uspešnu replikaciju HIV virusa (42).”
Immunosenescence and immune dysfunction in treated and untreated HIV-infected individuals
Unissa, A. N., Madheswaran, A., Inbanathan, A., Malathi, M., Vasantha, M., Kannan, M., Mangayarkarasi, S., Senthilnathan, R., Elamathi, V., Pradeep, A., et al. (2026) · The Indian Journal of Medical Research · doi:10.25259/ijmr_1597_2025
“30,31 32-34 Further, PD-1 blockade is also being investigated as a therapeutic strategy for preventing ageing-associated comorbidities, as it is established that blocking PD-1 activity can restore immunological responses, such as T-cell proliferation.”
BindingDB Entry 50043794: Telomere maintenance as a target for drug discovery.
BindingDB (2014) · UC San Diego · doi:10.7270/q2t43vkj
BindingDB (2024) · UC San Diego · doi:10.7270/q2mg7tw8
Metadata
- Authors
- Hukezalie, K. R., Thumati, N. R., Côté, H. C. F., & Wong, J. M. Y.
- Affiliations
- University of British Columbia (CA)
- Corresponding author
- Wong, Judy M. Y.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-11-15
- Volume
- 7
- Issue
- 11
- Pages
- e47505
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3499584
- OpenAlex
- W2149868956
- Cited by
- 84
- References
- 50
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 7 · 2023: 4 · 2022: 3 · 2021: 9 · 2020: 10 · 2019: 6 · 2018: 8 · 2017: 6 · 2016: 7 · 2015: 2 · 2014: 8 · 2013: 5
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Michael Smith Health Research BC
- National Institutes of Health
- Canadian Institutes of Health Research (551_5)
- National Institute of Allergy and Infectious Diseases
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- telomerase inhibition, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, HIV reverse transcriptase, off-target effects, tenofovir, abacavir, antiretroviral therapy, zidovudine, stavudine, didanosine, nevirapine, efavirenz, primer extension assay
- MeSH terms
- Tenofovir, Abacavir, Adenine, Alkynes, Cell Line, Cyclopropanes, Dose-Response Relationship, Drug, Humans, Zidovudine, Dideoxynucleosides, Didanosine, DNA Primers, Stavudine, Reverse Transcriptase Inhibitors, Telomerase, Anti-HIV Agents, Nevirapine, Benzoxazines, Organophosphonates, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.